FindTrial
Sign In

Expression and clinical significance of miRNAs in renal carcinoma

Expression and clinical significance of miRNAs in renal carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075488
Enrollment
Unknown
Registered
2023-09-06
Start date
2023-09-10
Completion date
Unknown
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal carcinoma

Interventions

experimental group:NA

Sponsors

Affiliated Hospital of Yangzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1) Renal cell carcinoma was diagnosed both before and after surgery; 2) Postoperative follow-up

Exclusion criteria

Exclusion criteria: 1) Postoperative pathology showed non-renal cell carcinoma;2) It is difficult to follow the interview after surgery

Design outcomes

Primary

MeasureTime frame
miRNA content in renal carcinoma specimens;—

Secondary

MeasureTime frame
Staging and grading of renal cell carcinoma;—

Countries

China

Contacts

Public ContactXiaoxiang Wang

Affiliated Hospital of Yangzhou University

1508038228@qq.com+86 189 3648 9811

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026